Sensydia Corp., a Westwood-based medical technology company, is making significant strides in non-invasive cardiac assessment. With a recent $3 million grant from the National Institutes of Health (NIH), Sensydia is poised to revolutionize the field by developing an innovative platform that utilizes artificial intelligence (AI) algorithms.

This breakthrough technology aims to provide clinicians with detailed heart assessments without the need for invasive procedures, opening up new possibilities for early diagnosis and personalized care.

Combining Expertise: Clinical Cardiology Meets Biomedical Engineering

Founded in 2015, Sensydia has assembled a team of experts from various disciplines, including clinical cardiology, biomedical engineering, and machine learning. Drawing upon their diverse backgrounds, the Sensydia team has developed a platform that integrates biosensors and AI algorithms. This handheld device offers rapid and non-invasive measurements of key cardiac metrics, such as ejection fraction, cardiac output, pulmonary artery pressure, and pulmonary capillary wedge pressure. By combining clinical expertise with cutting-edge technology, Sensydia is pushing the boundaries of cardiac assessment.

Traditional cardiac assessments, such as echocardiograms, provide a general picture of heart health. However, when further investigation is required, patients often undergo invasive procedures, such as catheterization. Sensydia’s platform aims to overcome these limitations by offering a comprehensive and non-invasive alternative. By leveraging AI algorithms and biosensors, clinicians can obtain detailed measurements without subjecting patients to hospital-based catheterization procedures.

Enabling Early Diagnosis: Personalized Care for Heart Disease

The ultimate goal of Sensydia’s platform is to enable early diagnosis and personalized care for heart disease. By providing real-time measurements of cardiac function, clinicians can swiftly identify potential issues and intervene proactively. Farhan Khawaja, president of the Orlando Health Heart & Vascular Institute, believes that non-invasive and real-time cardiac function measures will significantly improve patient lives. This groundbreaking technology has the potential to shift healthcare from the hospital setting to the comfort of patients’ homes.

Sensydia’s dedication to innovation has been acknowledged by the Food and Drug Administration (FDA). In 2018, the company received FDA clearance for non-invasive measurement of ejection fraction. This measurement indicates the percentage of blood leaving the heart with each contraction and serves as an important indicator of heart muscle health. Last year, the FDA granted Sensydia’s device and technology platform “breakthrough device designation” for measuring additional key cardiac metrics, including cardiac output, pulmonary artery pressure, and pulmonary capillary wedge pressure.

NIH Grant: Advancing Development and Clinical Testing

The recent $3 million grant from the National Heart, Lung, and Blood Institute, a component of the NIH, further accelerates Sensydia’s progress. This grant supports the development and clinical testing of machine-learning algorithms for Sensydia’s Cardiac Performance System (CPS) platform. The CPS platform aims to facilitate earlier detection and therapy guidance for patients with heart failure and pulmonary hypertension. The grant is awarded in two phases, with the second phase funding contingent on the successful completion of Phase I milestones.

In addition to the NIH grant, Sensydia recently announced raising $8 million in funding. Orlando Health Ventures, based in Orlando, Florida, led the funding round, which brought the total raised to $17.5 million. This funding will enable Sensydia to finalize the development of the CPS platform and submit it to the FDA for prioritized review as part of the agency’s Breakthrough Devices Program. The company aims to commercialize the platform and revolutionize heart-failure management.

With ongoing innovation, collaboration across disciplines, and substantial funding, Sensydia is at the forefront of transforming cardiac assessment. By harnessing the power of AI and non-invasive technologies, the company is paving the way for earlier diagnosis, personalized care, and improved patient outcomes in the realm of heart disease.